Oncolin Therapeutics Announces Its Lead Technology Has Shown To Be Effective In Treating Cancer In Animal Models

Main Category: Cancer / Oncology
Also Included In: Neurology / Neuroscience
Article Date: 16 Apr 2008 - 4:00 PDT

email to a friend   printer friendly   opinions  

Oncolin Therapeutics, Inc., (OTCBB:OCOL) (Oncolin) announces that one of its lead drug candidates has shown in preclinical testing that it extends the life of animals that have human tumors implanted in their brains. The early testing has yielded results in animals that are equivalent to that of Temodar®, which is one of the leading cancer treatments for brain cancer with annual revenues in excess of $500 million annually. This technology is covered under Oncolin's recent exclusive option to license from The University of Texas M.D. Anderson.

In further studies it was determined that the administration of a combination of our compound with Temodar® produces superior anti-tumor activity when compared to Temodar® alone, resulting in increased survival.

"Even though these tests are very early stage they have generated some very positive results which validate our theory of this treatment. We are continuing to undertake and complete the preclinical studies required for a goal of beginning a phase I trial by the beginning of 2009," said Dr. Donald Picker, President and COO.

Recent News

Oncolin Therapeutics Obtains an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

Oncolin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland, which provides the company the right to license the use of Genistein analogs for cancer treatment.

Oncolin Announces Its Research Program Receives Peer Reviewed National Institute of Health Grant of $179,000.

About Oncolin Therapeutics, Inc.

Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at http://www.oncolinthera.com.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company's ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin's future business and financial results, refer to Oncolin's Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.

Oncolin Therapeutics, Inc.

• Additional
• References
• Citations